SCHEMBL4774084

SCHEMBL4774084

CCC(CC)N1CCC2(CCN(C(=O)c3ccc(CN(Cc4ncc[nH]4)Cc4ncc[nH]4)cc3)CC2)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR4 P61073 3/20 0.45
HRH3 Q9Y5N1 4/20 0.44
CYP2D6 P10635 6/20 0.42
CYP3A4 P08684 5/20 0.42
USP2 O75604 2/20 0.42
CYP2C9 P11712 5/20 0.40
ALDH1A1 P00352 3/20 0.40
HTR2B P41595 2/20 0.40
TSHR P16473 1/20 0.40
CYP1A2 P05177 2/20 0.39
CYP2C19 P33261 2/20 0.39
HPGD P15428 2/20 0.39
HSD17B10 Q99714 2/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
HIF1A Q16665 1/20 0.39
MAPK1 P28482 2/20 0.38
GABRD O14764 1/20 0.38
GABRA1 P14867 1/20 0.38
GABRB1 P18505 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2696010 0.95 CXCR4 (0.48) CXCR4HRH3CYP2D6CYP3A4USP2
SCHEMBL2693522 0.94 CXCR4 (0.47) CXCR4HRH3CYP2D6CYP3A4CYP2C9
SCHEMBL4778156 0.90 CXCR4 (0.46) CXCR4HRH3CYP2D6CYP3A4USP2
SCHEMBL2696089 0.87 CXCR4 (0.50) CXCR4HRH3CYP2D6CYP3A4USP2
SCHEMBL2696617 0.85 CXCR4 (0.44) CXCR4HRH3ALDH1A1
SCHEMBL2695184 0.85 CHRM2 (0.41) CXCR4HRH3HTR2B
SCHEMBL2693801 0.85 CXCR4 (0.48) CXCR4HRH3CYP2D6CYP3A4USP2
SCHEMBL2695977 0.85 CXCR4 (0.60) CXCR4HRH3CYP2D6CYP3A4USP2
SCHEMBL2694091 0.85 CXCR4 (0.51) CXCR4HRH3CYP2D6CYP3A4USP2
SCHEMBL1206718 0.84 HRH3 (0.52) CXCR4HRH3HTR2BMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8519124-B2 Chemokine receptor antagonists and use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2013-08-27 US claimed
EP-1961744-B1 BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF ONO PHARMACEUTICAL CO (JP) 2013-04-17 EP claimed
US-8519124-B2 Chemokine receptor antagonists and use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2013-08-27 US disclosed
EP-1961744-B1 BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF ONO PHARMACEUTICAL CO (JP) 2013-04-17 EP disclosed
US-20120207765-A1 CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2012-08-16 US disclosed
EP-1961744-A1 BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2008-08-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120207765-A1 CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF CXCR4, CXCR3, CXCR1 CXCR4 1/4885HRH3 548/4885CYP2D6 2851/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.